+67,943.5%
AXON vs GSK
+195.0%
+67,748.5%
-91.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -18.2% | -0.2% | -18.0% | -18.1% |
| 7D | -26.8% | +1.7% | -28.5% | -27.3% |
| 30D | -22.9% | +7.0% | -29.9% | -25.2% |
| 3M | -40.1% | -2.7% | -37.4% | -39.5% |
| 6M | -18.9% | +1.4% | -20.3% | -19.9% |
| YTD | -44.9% | +5.3% | -50.2% | -47.3% |
| 1Y | -46.7% | +10.6% | -57.3% | -50.2% |
| 3Y | +44.3% | +62.6% | -18.3% | +6.9% |
| 5Y | +71.4% | +41.7% | +29.7% | +32.0% |
| 10Y | +1,324.0% | +104.7% | +1,219.3% | +754.7% |
| All | +67,943.5% | +195.0% | +67,748.5% | +29,601.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling